Following Phase II testing, a drug is tested in a large-scale setting (several hundred to several thousand patients) to determine effectiveness, benefits, and the range of possible adverse reactions. Most Phase III studies are randomized and double blinded, and typically last several years. Usually, two well-controlled studies are necessary to establish efficacy. Once Phase III trials are successfully completed, a pharmaceutical company can request FDA approval for marketing the drug, by filing a New Drug Application (see NDA).
Glossary
Phase III
02.27.12
-
-
Drug Development
Solving the Pharma Talent Crunch
Addressing talent shortages in today's pharmaceutical sectorJim Sykes, Managing Director, Pharmaceutical & Life Sciences, Alexander Mann Solutions
-
Promotions & Moves
Akebia Therapeutics Names CMO
Jain to lead clinical development of the company’s HIF pipeline
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
Selexis SA and OSE Immunotherapeutics Enter Pact
Sign agreement for the development of OSE's interleukin receptor 7 antagonist
-
Clinical Trials | CRO News | Information Technology
CROS NT Expands Medidata Pact
Will offer customers Medidata’s next-gen EDC and RTSM systems
